Gabriel Morris
Director of Finance/CFO bij IMMIX BIOPHARMA, INC.
Vermogen: 991 054 $ op 31-03-2024
Profiel
Gabriel A.
Morris is currently the Chief Financial Officer & Director at Immix Biopharma, Inc., Managing Partner at Alwaysraise LLC, and President at Nexcella, Inc. He previously worked as the Chief Operating Officer at Campbell & Co. LP and as the Chief Financial Officer at ZAP Surgical Systems, Inc. Mr. Morris completed his undergraduate degree at The Trustees of Columbia University in The City of New York.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
IMMIX BIOPHARMA, INC.
1.26% | 14-08-2023 | 322 819 ( 1.26% ) | 991 054 $ | 31-03-2024 |
Actieve functies van Gabriel Morris
Bedrijven | Functie | Begin |
---|---|---|
IMMIX BIOPHARMA, INC. | Director of Finance/CFO | 01-03-2021 |
Alwaysraise LLC | Corporate Officer/Principal | 01-01-2020 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | President | - |
Eerdere bekende functies van Gabriel Morris
Bedrijven | Functie | Einde |
---|---|---|
Campbell & Co. LP
Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Chief Operating Officer | 03-01-2021 |
ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Director of Finance/CFO | 01-01-2020 |
Opleiding van Gabriel Morris
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Campbell & Co. LP
Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Finance |
ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Technology Services |
Alwaysraise LLC | |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |